日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer

在随机3期TOPAZ-1研究中,度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌的免疫介导不良事件

Antonuzzo, Lorenzo; Takahashi, Hidenori; Park, Joon Oh; Sookprasert, Aumkhae; Gillmore, Roopinder; Yang, Sheng-Shun; Cundom, Juan; Petrova, Mila; Vaccaro, Gina; Holmblad, Marielle; Żotkiewicz, Magdalena; Wang, Julie; Rokutanda, Nana; Oh, Do-Youn

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

帕博利珠单抗联合卡铂和紫杉醇作为复发/转移性头颈部鳞状细胞癌一线治疗(KEYNOTE-B10):一项单臂IV期试验

Dzienis, Marcin; Cundom, Juan; Fuentes, Christian Sebastian; Spreafico, Anna; Nordlinger, Melanie; Pastor, Andrea Viviana; Alesi, Erin; Neki, Anterpreet; Fung, Andrea S; Figueiredo Lima, Iane Pinto; Oppelt, Peter; da Cunha Junior, Geraldo Felicio; Burtness, Barbara; Franke, Fabio Andre; Tseng, Jennifer E; Joshi, Abhishek; McCarthy, Joy; Swaby, Ramona; Sidi, Yulia; Gumuscu, Burak; Naicker, Niroshini; de Castro, Gilberto Jr

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

乐伐替尼联合帕博利珠单抗对比标准治疗方案治疗既往接受过治疗的转移性结直肠癌:随机、开放标签、III期LEAP-017研究的最终分析

Kawazoe, Akihito; Xu, Rui-Hua; García-Alfonso, Pilar; Passhak, Maria; Teng, Hao-Wei; Shergill, Ardaman; Gumus, Mahmut; Qvortrup, Camilla; Stintzing, Sebastian; Towns, Kathryn; Kim, Tae Won; Shiu, Kai Keen; Cundom, Juan; Ananda, Sumitra; Lebedinets, Andrey; Fu, Rong; Jain, Rishi; Adelberg, David; Heinemann, Volker; Yoshino, Takayuki; Elez, Elena